| First Author | Brightbill HD | Year | 2018 |
| Journal | Nat Commun | Volume | 9 |
| Issue | 1 | Pages | 179 |
| PubMed ID | 29330524 | Mgi Jnum | J:258357 |
| Mgi Id | MGI:6114874 | Doi | 10.1038/s41467-017-02672-0 |
| Citation | Brightbill HD, et al. (2018) NF-kappaB inducing kinase is a therapeutic target for systemic lupus erythematosus. Nat Commun 9(1):179 |
| abstractText | NF-kappaB-inducing kinase (NIK) mediates non-canonical NF-kappaB signaling downstream of multiple TNF family members, including BAFF, TWEAK, CD40, and OX40, which are implicated in the pathogenesis of systemic lupus erythematosus (SLE). Here, we show that experimental lupus in NZB/W F1 mice can be treated with a highly selective and potent NIK small molecule inhibitor. Both in vitro as well as in vivo, NIK inhibition recapitulates the pharmacological effects of BAFF blockade, which is clinically efficacious in SLE. Furthermore, NIK inhibition also affects T cell parameters in the spleen and proinflammatory gene expression in the kidney, which may be attributable to inhibition of OX40 and TWEAK signaling, respectively. As a consequence, NIK inhibition results in improved survival, reduced renal pathology, and lower proteinuria scores. Collectively, our data suggest that NIK inhibition is a potential therapeutic approach for SLE. |
